Manuel Corpas is a lecturer in Genomics at the University of Westminster, London, and serves as Scientific Director of Cambridge Precision Medicine, a company associated with the Cambridge University business accelerator (ideaSpace). Manuel is an expert in providing clinical genomics interpretation services to healthcare institutions. He is also a visiting tutor/lecturer at the University of Cambridge and director of the expert course in clinical genetics and personalized medicine at the International University of La Rioja.
He has more than 60 scientific publications in international journals and one book. He graduated in Biomedical Sciences from the University of Navarra, with a master’s and PhD in Bioinformatics from the University of Manchester, and 3.5 years of postdoctoral experience at the Sanger Institute, Cambridge, UK.
Dr John Maher is the scientific founder and chief scientific officer of Leucid Bio. He is also a clinical immunologist who leads the "CAR Mechanics" research group within King's College London. He played a key role in the early development of second generation (CD28) CAR technology while a visiting fellow at Memorial Sloan Kettering Cancer Center, an approach that has achieved clinical impact in haematological malignancies. His research group is focused on the development of adoptive immunotherapy using CAR engineered and gamma delta T-cells, with a primary emphasis on solid tumour types. In addition, he is a consultant immunologist within King's Health Partners and Eastbourne Hospital.
Jenny has an MA in Experimental Psychology from Oxford University, a PhD in the epidemiology of schizophrenia from the University of Cambridge and completed post-doctoral work at Massachusetts General Hospital and the Broad Institute of Harvard and MIT. She joined Cambridge Cognition in 2008 and worked i Jenny has an MA in Experimental Psychology from Oxford University, a PhD in the epidemiology of schizophrenia from the University of Cambridge and completed post-doctoral work at Massachusetts General Hospital and the Broad Institute of Harvard and MIT. She joined Cambridge Cognition in 2008 and worked in the clinical trial, healthcare, and R&D functions before joining the senior management team in 2014 and becoming CSO in 2016.
She has worked on the design and analysis of more than 100 cognitive trials and is the author of 60+ scientific publications and six patents. She has led IP strategy, KOL networking and the scientific validation of medical devices for regulatory approvaln the clinical trial, healthcare, and R&D functions before joining the senior management team in 2014 and becoming CSO in 2016. She has worked on the design and analysis of more than 100 cognitive trials and is the author of 60+ scientific publications and six patents. She has led IP strategy, KOL networking and the scientific validation of medical devices for regulatory approval.
Christoph A. Merten is a Professor for biomedical microfluidics at the Swiss Federal Institute of Technology (EPFL; www.epfl.ch/labs/lbmm) in Lausanne, Switzerland. He also holds an adjunct position at the Ludwig Institute for Cancer Research (LICR).
In parallel to his academic career, Christoph has gained significant industry and entrepreneurship experience: He successfully commercialized microfluidic technology for genomic applications (e.g. licensed to Diagenode for the BioRuptor OneTM), collaborated with big pharma (including Roche and GSK) and worked for many years as a consultant. Furthermore, he is the scientific founder and chief consultant of Veraxa Biotech (www.velabs-therapeutics.com), an antibody discovery company that successfully secured 2 investment rounds within just one year and which is constantly growing and acquiring deals with large pharma industry.
Christoph holds a Ph.D. in biochemistry (directed evolution) from the University of Frankfurt and did postdoctoral studies at the MRC Laboratory of Molecular Biology (Cambridge, UK) and the Institute de Science et d’Ingénierie Supramoléculaires (ISIS) in Strasbourg, France. Before moving to Switzerland he lead a group at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany
Andrew has been leading translational biology teams for nearly 20 years with international industrial experience developing both small and large molecule oncology drugs. He began his career on the faculty of the University of Kentucky before joining N of One Therapeutics, MedImmune (USA) and subsequently AstraZeneca (UK). Andrew has brought multiple therapeutic candidates into and through clinical development including immunotherapies, antibody/drug conjugates, DNA damage/repair modulators and classical cell signalling inhibitors.
Andrew has a BSci degree from the University of Toronto in Canada, and a PhD in molecular genetics from the University of North Carolina at Chapel Hill. He has published over 40 papers in peer-reviewed journals and serves on the Molecular and Cellular Medicine Board of the MRC (UK).
Dr Milena Kalaitsidou PhD is the Principal Scientist in the Pre-Clinical Safety Group at the Department of Research at Instil Bio. She attained a Masters in Immunology and Immunogenetics and PhD in Cancer Sciences from the University of Manchester. Her PhD focused on the understanding T cell responses towards leukemic fusion proteins and the potential application in cell therapy treatments. Subsequently, she led projects developing CAR chimeric antigen receptor (CAR) T-cell therapy for ovarian cancer in collaboration with Oxford Biomedica and the University of Manchester.
Her adoptive cell therapy interests were further cultivated during her fellowship between University of Manchester and GSK, whereby she worked on developing tumour infiltrating lymphocyte (TIL) therapy with or without engineering for an array of cancer types. She continued the TIL therapy development by joining Instil Bio where she has led TIL engineering projects from concept to clinical application
Dr Stuart Hannah is CEO of Microplate Dx Ltd, an innovative, award-winning diagnostics-focussed spinout company from the University of Strathclyde in Glasgow. Dr Hannah has a First-Class Honours degree and PhD in Electronic & Electrical Engineering from Strathclyde and has 10+ years’ academic and industrial experience in developing biosensors and diagnostics for healthcare. Dr Hannah has a wide range of interests from life sciences, in-vitro diagnostics, antimicrobial resistance (AMR) and electrochemistry, to algorithm development, data analytics, product development and commercialisation.
As full-time CEO and co-founder of Microplate Dx Limited, Dr Hannah oversees a dedicated team of professionals who are aiming to become world leaders in rapid, antibiotic susceptibility testing at the point-of-care for a wide range of pathogens including urinary tract infections, sepsis, fungal infections etc. Microplate Dx’s mission is to eliminate ‘best-guess’ antibiotic prescribing, reducing the burden of antimicrobial resistance and saving countless lives.
Amin Hajitou completed his PhD at The University of Liège, Belgium. During his PhD work he acquired extensive experience in gene delivery technologies. Then, he completed his postdoctoral training at the MD-Anderson Cancer Center in Texas-USA, where he gained expertise in bacteriophage (phage)-guided delivery of nucleic acids. Importantly, he designed a novel hybrid phage vector for targeted gene transfer and showed first success of systemic gene targeting to cancer in vivo. His team and independent groups reported efficacy of intravenous cancer gene therapy in rodents and pet dogs. Phase 1 clinical trials in cancer patients have started in 2022. In 2008, Hajitou established his research team as a Lecturer, at Imperial College London, where he became Senior Lecturer in 2013, then Reader in 2016 and Professor of Targeted Therapeutics in 2019. His research team has become a leading authority in phage-guided delivery technologies. His leadership in the field has resulted in various awards, patent applications and two start-up companies.
Nagy is a founder and Head of R&D of MiNA Therapeutics. For over three decades Nagy has been at the forefront of clinical research and clinical practice in cancer. He pioneered the first clinical trial in the use of adenovirus and plasmid for the treatment of liver cancer, as well as the use of plasmid gene therapy in hydrodynamic gene delivery. Currently, he is driving the development of an saRNA drug (a new class of medicines) which is currently being trialed in patients with liver cancer in eight UK centres, and sites in Singapore and Taiwan (OUTREACH study, ClinicalTrials.gov ID NCT02716012), a second trial in patients with solid tumours (TIMEPOINT study, ClinicalTrials.gov ID NCT 04105335) in the UK, USA, Europe, Singapore and Taiwan and OUTREACH2 study, which is a randomised phase II follow-on study in patient with viral HCC (ClinicalTrials.gov ID NCT 04710641). He has published widely in gene therapy, stem cell therapy, oligonucleotides, endoscopy and surgery. Previously Nagy was founder and Chairman of EMcision Limited (acquired by Boston Scientific Inc in 2018). Nagy is Lead Clinician and Head of the Department of HPB Surgery at Imperial College London